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Between April 1975 and May 1995, 25 pediatric patients on one hospital service 
underwent extended left ventricular septal myectomy because of hypertrophic 
obstructive cardiomyopathy. Ages ranged from 2 months to 20 years (mean, 
11.2 years). Seventeen patients had moderate to severe mitral valve insuffi- 
ciency. Medical therapy had failed in all patients and one patient had 
undergone dual-chamber pacemaker implantation without improvement. Left 
ventricular outflow tract gradients ranged from 50 to 154 mm Hg (mean, 
99.9 -+ 25.2). Concomitant cardiac procedures included mitral valve repair 
(n = 2), automatic mplantable cardioverter defibrillator implantation ( = 1), 
and closure of atrial septal defect (n = 1). Intraoperative premyectomy left 
ventricular outflow tract gradients ranged from 20 to 117 mm Hg (mean, 
60.4 - 26.2) and postmyectomy gradients ranged from 0 to 20 mm Hg (mean, 
6.6 +- 5.9). Postmyectomy mitral insufficiency was reduced to a regurgitant 
fraction of 0% to 12%, and no patient required mitral valve replacement. One 
patient required a pacemaker because of complete heart block; on subsequent 
follow-up, normal sinus rhythm had returned. There was no early mortality 
and no instance of aortic or mitral valve injury or ventricular septal defect. 
Follow-up ranged from 10 months to 20 years (mean, 6.4 years). There were no 
late deaths. Left ventricular outflow tract gradients by echocardiography were 
a mean of 14.2 mm Hg with a median of 5.0 mm Hg. All patients had normal 
sinus rhythm. Reoperation because of recurrent left ventricular outflow tract 
obstruction was necessary in two patients at 3.2 years and 12.4 years after 
initial myectomy, respectively. All patients but one have New York Heart 
Association class I or II function. We conclude that extended septal myectomy 
is a safe and effective means of relieving cardiac symptoms and left ventricular 
outflow tract obstruction in pediatric patients with severe hypertrophic ob- 
structive cardiomyopathy unresponsive to medical management, and late 
survivorship compares favorably with the natural history of the disease. 
(J Thorac Cardiovasc Surg 1996;112:1589-99) 
H ypertrophic obstructive cardiomyopathy (HOCM) is an intriguing primary myocardial disease based 
on distinct genetic mutations. 1' 2 The heterogeneity of 
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this disease process is demonstrated byits wide varia- 
tion in clinical symptoms, hemodynamic characteris- 
tics, natural history, age at presentation, and risk for 
sudden death. For patients at our institution who have 
severe HOCM that is unresponsive to medical man- 
agement, an extended left ventricular septal myectomy 
(LVM) has been offered. 3 Several recent surgical 
series have confirmed the effectiveness of LVM in 
reducing symptoms and systolic pressure gradients 
across the left ventricular outflow tract (LVOT), and 
some of the data indicate an improvement in late 
patient survival. 4-8 Most surgical reports include only 
adults or patients over a wide age spectrum without 
separate analysis of results for the pediatric subset. 
This current study assesses the results in a series of 
pediatric patients who underwent LVM because of 
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Fig. 1. Pie chart of age distribution, pt, Patients. 
severe HOCM on one surgical service during a 20-year 
interval. 
Patients and methods 
Patients. Between April 1975 and May 1995, 25 pa- 
tients (13 male and 12 female) who were 20 years old or 
younger underwent primary operation for HOCM on one 
surgical service. Ages ranged from 2 days to 19 years 
(mean, 7.7 years; median, 9.0 years) at diagnosis and from 
2 months to 20 years (mean, 11.2 years; median, 14.0 
years) at operation (Fig. 1). The diagnosis of HOCM was 
based on clinical evaluation and on echocardiography or 
cardiac catheterization, or both. Patients with severe 
obstruction of both right and left ventricular outflow tracts 
were excluded and their cases will be reported separately. 
Preoperative clinical and hemodynamic data are summa- 
rized in Table I. In 20 patients (80%), the indication for 
operation was refractory symptoms despite maximal med- 
ical therapy (Table I); duration of treatment ranged from 
2.6 months to 7.2 years (mean, 2.2 years). Five patients 
were free of symptoms; these patients had resting LVOT 
gradients of 80 mm Hg or more and were thought o be at 
increased risk for death, similar to patients with severe 
valvular aortic stenosis. All patients had preoperative 
resting or inducible LVOT gradients of 50 mm Hg or 
more. One patient had undergone dual-chamber pace- 
maker implantation elsewhere without improvement of 
symptoms or LVOT gradient. 
Associated cardiac diagnoses included moderate to 
severe mitral valve insufficiency (n = 17), mild aortic 
insufficiency (n = 3), atrial septal defect (n = 1), bicuspid 
aortic valve (n = 1), and muscle bridge over the left 
anterior descending coronary artery (n = 1). Three pa- 
tients had a history of serious ventricular arrhythmia 
(ventricular tachycardia, n = 2; easily inducible ventricu- 
lar fibrillation on electrophysiologic study, n = 1). Echo- 
cardiographic gradients were measured as maximum in- 
stantaneous gradients and cardiac catheterization 
gradients were measured as peak systolic gradients. Pre- 
operative gradients ranged from 50 to 154 mm Hg (mean, 
99.9 -+ 25.2) as determined by echocardiography (n = 12), 
cardiac catheterization (  = 4), or both (n = 9). 
Current surgical techniques. Pressures are measured 
in all four cardiac chambers and in the pulmonary artery 
and aorta before the start of cardiopulmonary b pass. 
Standard cardiopulmonary b pass with moderate (25 ° to 
32 ° C) hypothermia s used. Protecting the severely hyper- 
trophied myocardium during aortic crossclamping is espe- 
cially important. We prefer multiple-dose cold blood 
cardioplegia combined with topical cooling. A transverse 
aortotomy is made anteriorly and the incision is extended 
rightward into the noncoronary sinus. The aortic valve 
cusps are retracted to expose the hypertrophied septum 
and region of septal contact with the anterior leaflet of the 
mitral valve, which typically produces fibrotic endocardial 
thickening (friction lesion). The thickness and extent of 
the septal hypertrophy are evaluated by intraoperative 
transesophageal chocardiography, supplemented asindi- 
cated with bimanual palpation of the heart between the 
LVOT and the anterior surface of the left ventricle. 
The septal resection is begun by making two parallel 
longitudinal incisions in the septum, the first beneath the 
nadir of the right coronary cusp and the second beneath 
the commissure between the right and left cusps (Fig. 2). 
Accurate placement of these incisions protects the main 
conduction bundle. The incisions are connected superiorly 
with a third incision that is continued into the septum, and 
a generous wedge of muscle is resected. The resection is 
continued apically to at least the level of the papillary 
muscles. Exposure of the septum may be facilitated by 
posterior displacement of the anterior wall of the left 
ventricle. The myocardial groove in the septum is deep- 
ened as necessary by further resection with a scalpel or 
pituitary rongeur; if exposure is difficult, the groove in the 
septum is incised with a scalpel and widened by digital 
manipulation. Additional myocardium is resected from 
this groove leftward to the anterior leaflet of the mitral 
valve. For patients who have associated midventricular 
obstruction, further muscle resection is done around and 
below the papillary muscles toward the apex. These 
surgical techniques collectively are termed an extended 
septal myectomy. The adequacy and distal extent of the 
resection are evaluated by inspection and digital palpa- 
tion. Occasionally, a distorted anterior mitral leaflet is 
repaired by a plicating suture, 9 and an anterior papillary 
muscle that appears to be located too far anteriorly is 
released by an incision made anterior to the base of the 
muscle)0, 11 
Placement of an insulating pad behind the left ventricle 
permits safe rewarming during aortic closure. We prefer 
to defibrillate the heart with warm blood cardioplegic 
solution rather than electric defibrillation, which some- 
times requires multiple shocks. Pressure measurements 
are repeated in the left ventricle and ascending aorta after 
the patient is weaned from cardiopulmonary b pass and 
hemodynamic conditions are stabilized. The degree of 
mitral valve insufficiency is assessed before and after 
cardiopulmonary b pass by transesophageal chocardiog- 
raphy, often supplemented with double-sampling dye 
curves done by injection of indocyanine green dye into the 
apex of the left ventricle and sampling simultaneously in 
the dome of the left atrium and the aorta, a technique that 
provides more accurate quantitation of the mitral insuffi- 
ciency. 
Statistical analysis. Follow-up information was obtained 
from correspondence with patients and referring physicians 
and from telephone interviews. Postoperative freedom from 
reoperation was calculated by the Kaplan-Meier method. 
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Table I. Clinical and hemodynamic data 
Before myectomy After myectomy 
No. % No. % p Value 
NYHA class 
I 5 20 
II 10 40 
III 9 36 
IV 1 4 
Mean 2.24 _+ 0.83 
Symptoms 
Dyspnea 18 72 
Angina 12 48 
Syncope 5 20 
Palpitations 2 8 
Hemodynamics 
Mean LVOT gradient (ram Hg) 99.9 ± 25.2 
Mean intraoperative LVOT gradient (ram Hg) 60.4 _+ 26.2 
Moderate or severe MV insufficiency 17 68 
Rhythm 
Normal sinus 25 100 
Medications 
/3-Adrenergic antagonists 17 68 
Calcium channel antagonists 4 16 
Both of the above 3 12 










14.2 -+ 27.7 













MV,, Mitral valve. 
The rank sum test was used to compare continuous variables. 
Statistical significance was accepted at p < 0.05. 
Results 
Early results. A primary transaortic extended 
LVM was done in all 25 patients. Concomitant 
cardiac procedures included plication of the ante- 
rior leaflet of the mitral valve (n = 2), automatic 
implantable cardioverter defibrillator (AICD) im- 
plantation (n = 1), closure of atrial septal defect 
(n = 1), and unroofing of a coronary artery muscle 
bridge (n = 1). Aortic crossclamp times ranged from 
11 to 53 minutes (mean, 35.3). Intraoperative LVOT 
gradients ranged from 20 to 117 mm Hg (mean, 
60.4 _+ 26.2) before myectomy and from 0 to 20 mm 
Hg (mean, 6.6 +_ 5.9) after myectomy (p < 0.0001). 
No patients in this group required reinstitution of 
cardiopulmonary b pass for relief of significant re- 
sidual LVOT gradient after initial LVM; 22 patients 
(88%) had a gradient of 15 mm Hg or less. 
The moderate or severe mitral regurgitation 
present before operation in 17 patients with HOCM 
(Table I) was successfully eliminated in 16 patients 
with LVM alone (n = 14) or LVM combined with 
an anterior mitral leaflet plication (n = 2). None of 
the 16 patients showed significant (greater than 
20%) mitral insufficiency by double-sampling dye 
curves. Moderate residual mitral insufficiency was 
present in the 2-month-old infant. No patients re- 
quired mitral valve replacement. 
There were no early deaths. Two patients re- 
quired temporary intraaortic balloon pump support 
to wean them from cardiopulmonary b pass. Two 
patients required placement of an AICD after epi- 
sodes of ventricular tachycardia or fibrillation at 1 
and 2 weeks after operation, respectively; one of the 
two patients was known to have spontaneous ven- 
tricular tachycardia before operation. One patient 
underwent placement of a pacemaker because of 
complete heart block that was still present on post- 
operative day 8; on subsequent follow-up 1 year 
later he had normal sinus rhythm. Acute constrictive 
pericarditis developed in one patient who had re- 
ceived AICD patches intraoperatively and this ne- 
cessitated pericardiectomy on postoperative day 8. 
There were no instances of aortic or mitral valve 
injury or surgically created ventricular septal defect. 
Hospital stay ranged from 5 to 48 days (median, 8; 
mean, 13.1). For those patients who did not require 
subsequent pericardiectomy, pacemaker, or AICD, 
the mean hospital stay was 8.5 days. Twenty patients 
were discharged from the hospital receiving /3-ad- 
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Fig. 3. Diagram of freedom from reoperation because of 
recurrent LVOT obstruction. 
Fig. 2. Anatomic haracteristics of hypertrophic obstruc- 
tive cardiomyopathy. A, Surgeon's view through transverse 
aortotomy. Right coronary cusp is located anteriorly and 
left cusp is located posteriorly and to left. Gentle retrac- 
tion of aortic usps, combined with posterior displacement 
of left ventricle as needed, exposes ventricular septum and 
anterior leaflet of mitral valve (AL MV). B, Sagittal view 
through opened left ventricle showing membranous sep- 
tum below commissure between right and noncoronary 
cusps, distribution of left bundle branches, septal hyper- 
trophy, and anterior leaflet of mitral valve with its subval- 
vular apparatus. C, Extent of initial septal resection is 
shown. Resection is then extended leftward to anterior 
leaflet of mitral valve and apically to relieve all midven- 
tricular obstruction. RCA, Right coronary artery; LCA, 
left coronary artery. 
renergic antagonists, four receiving calcium channel 
antagonists, and one receiving digoxin and amioda- 
rone. 
Late  resu l ts .  Follow-up was obtained in all 25 
patients and ranged from 10 months to 20 years 
(mean, 6.4 _+ 5.2 years; median, 4.4 years) for a total 
of 159.5 patient-years. Ages at the time of most 
recent contact ranged from 3.9 to 40.9 years (mean, 
17.5). There were no late deaths. 
Recurrent symptoms and hemodynamically sig- 
nificant LVOT gradients developed in two patients 
necessitating reoperation at 3.2 and 12.4 years after 
initial myectomy, respectively. Freedom from reop- 
eration because of recurrent LVOT obstruction was 
94.4% + 5.4% at 5 years (Fig. 3). The first patient 
who required reoperation was 1 year old when 
HOCM was diagnosed. At age 2 years, echocardi- 
ography and cardiac catheterization showed a rest- 
ing LVOT gradient of 100 mm Hg, and the patient 
underwent LVM. The intraoperative postresection 
LVOT gradient was 7 mm Hg, and there was no 
detectable mitral valve insufficiency. The patient did 
well during the following 2.5 years until exertional 
dyspnea and mild chest pain developed. Cardiac 
catheterization a d echocardiography demonstrated 
an outflow gradient of 80 mm Hg. At age 5 years, 3.2 
years after initial LVM, she underwent repeat my- 
ectomy. Seven years later she is completely free of 
symptoms and has an LVOT gradient of only 12 mm 
Hg. 
The second patient who required reoperation was 
diagnosed with HOCM in infancy. At age 31A years 
she had significant symptoms (New York Heart 
Association [NYHA] class III) with an LVOT gra- 
dient of 60 mm Hg. LVM was done; the intraoper- 
ative postresection LVOT gradient was 15 mm Hg 
and there was no evidence of important mitral or 
aortic valve insufficiency. She did well during the 
following 10 years until routine follow-up echocar- 
diography demonstrated increasing LVOT obstruc- 
tion (50 mm Hg gradient). During the next 2 years, 
the LVOT gradient increased to 80 mm Hg and 
significant dyspnea nd chest pain developed. She 
also had severe, unexplained aortic insufficiency. At 
age 16 years, 12.4 years after initial LVM, she 
underwent reoperation for myectomy, aortoven- 
triculoplasty (Konno procedure), and aortic valve 
replacement with an aortic homograft. Intraopera- 
tively, there was massive septal hypertrophy and the 
previous resection site had completely filled in with 
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Preoperative Postoperative 
Class IV Class I Class III 
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Class II Class I 
Fig. 4. Pie charts showing preoperative NYHA func- 
tional classification (lefipanel) and NYHA classification at
most recent contact (right panel), pt, Patients. 
septal tissue. She is currently a 20-year-old college 
student and is completely free of symptoms with an 
LVOT gradient of 12 mm Hg. 
A third patient was born with severe cardiac 
failure; the diagnosis of HOCM was made on the 
second day of life (she was in NYHA class IV). 
She was initially treated medically, but because of 
persistent cardiac failure, severe mitral valve in- 
sufficiency, and an LVOT gradient of 61 mm Hg, 
she underwent LVM at age 2 months. The pos- 
tresection intraoperative LVOT gradient was 16 
mm Hg; there was no gradient across the right 
ventricular outflow tract. Mitral insufficiency was 
graded as moderate. At the time of hospital 
discharge, echocardiography detected an LVOT 
gradient of 40 mm Hg and moderate mitral valve 
insufficiency. She was treated with /3-adrenergic 
antagonists and calcium channel antagonists, but 
during the next 5 years severe LVOT and right 
ventricular outflow tract gradients developed (130 
and 41 mm Hg, respectively) and she was in 
functional class III. Because of the progressive 
global nature of the HOCM in this case, the 
resulting severe biventricular outflow tract ob- 
structions, and the high risk associated with biven- 
tricular septal resection in pediatric patients, this 
patient recently underwent successful heart trans- 
plantation. 
Of the remaining 24 patients, 21 were free of 
symptoms (NYHA class I) at the time of most 
recent contact, and 3 had only mild limitations 
(NYHA class II) (Fig. 4). The mean NYHA func- 
tional class was 2.24 _+ 0.83 before operation and 
1.12 + 0.44 after operation (p < 0.01 by the paired 
t test). The prevalence of angina, syncope, and 
dyspnea decreased substantially: 14 (78%) of 18 













Preop Late postop 
Fig. 5. Diagram of mean LVOT gradients measured be- 
fore operation (Preop) and at late follow-up (Latepostop) 
by echocardiography. 
with angina (p < 0.001), and 5 (100%) of 5 with 
syncope had complete relief of these symptoms after 
operation. 
In accordance with a philosophy of maintenace of 
medical therapy after operation, 14 patients are 
being treated with/3-adrenergic antagonists alone, 5 
patients with calcium channel antagonists alone, 2 
patients with both, 3 patients with amiodarone in 
combination with either/3-adrenergic antagonist or 
calcium channel antagonist, and 1 patient with a 
combination of disopyramide and a calcium channel 
antagonist. At most recent contact, all patients had 
normal sinus rhythm. 
Late echocardiographic information was available 
in 24 patients a mean of 5.3 _+ 4.5 years after LVM. 
Mitral valve insufficiency was present in 9 patients 
(mild in 8, moderate in 1) and mild aortic insuffi- 
ciency was present in 3 patients. The mean LVOT 
gradient was 14.2 mm Hg and the median was 5.0 
mm Hg. Excluding the youngest patient, who was 2 
months old at operation and who was the only 
patient with class III symptoms at follow-up, the 
mean LVOT gradient was 8.9 mm Hg. These reduc- 
tions in gradients (measured by echocardiography) 
compare favorably with the mean premyectomy 
gradient of 99.9 mm Hg (measured by echocardiog- 
raphy or cardiac catheterization, or both (p < 
0.0001) (Fig. 5). 
Discuss ion  
The clinical course and prognosis of HOCM in 
children, as in adults, is highly variable because of a 
wide spectrum of anatomic and physiologic abnor- 
malities. Maron and coworkers 12 have suggested 
that in children and adolescents with HOCM the 
rate of progression of the disease may be more rapid 
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Fig. 6. Patient survival in current surgical seriescom- 
pared with survival in pediatric patients with HOCM 
treated nonsurgically (Dx child) as reported by McKenna 
and associates. 14 
than in the adult HOCM population and that the 
factors responsible for body growth and develop- 
ment characteristics of childhood and adolescence 
may have an important role in inducing this progres- 
sion. 
Negative inotropic agents including/3-adrenergic 
antagonists, calcium channel antagonists, and diso- 
pyramide have been used in an attempt to reduce 
the degree of LVOT obstruction in patients with 
HOCM.7, 13 Although these agents have improved 
symptoms in many patients, there is little evidence 
that they improve patient survival. 13' 14 Treatment of 
children and young adults with HOCM is compli- 
cated by several factors including noncompliance 
with long-term medical therapy, intolerance to the 
medications (especially /3-adrenergic antagonists), 
continued participation i strenuous physical activ- 
ities, and an increased risk of sudden death com- 
pared to older patients. 14-16 
Sudden cardiac death is an unpredictable event in 
HOCM and is the most common mode of death in 
patients with this disease. 14' 17 The reported annual 
mortality rate for adult patients with unoperated 
HOCM is 3% to 4% per year, TM 17 but for children 
with HOCM the mortality rate is 4% to 6% per 
year. 14 Shah and coworkers 17 found no correlation 
between severity of symptoms and the occurrence of 
sudden death. McKenna 14 and Fananapazir is and 
their colleagues have identified ahistory of syncope, 
a family history of sudden death, and the diagnosis 
of HOCM in childhood as prognostic markers for 
sudden death. Congestive heart failure in infants 
with HOCM is a particularly unfavorable prognostic 
sign; 9 of 11 such infants died in the first year of life 
in the report by Maron and coworkers, 16and the 
only patient in the present series who was not in 
class I or II at follow-up was the patient who was 
born with severe heart failure. Maron and col- 
leagues 15 found that 23 of 26 patients without 
symptoms who died suddenly were younger than ge 
25 years. The presence of obstruction may also be a 
factor in sudden death; in one review of 31 children 
with hypertrophic ardiomyopathy, sudden death 
occurred in 40% of patients with obstruction com- 
pared with only 8% of patients without obstruc- 
tion. 19 
It is generally agreed today that transaortic septal 
myectomy is the most appropriate surgical treat- 
ment for patients with HOCM and severe symptoms 
unresponsive tomedical therapy. 3-7' 20 Most surgical 
articles report results and long-term survival after 
myectomy in adults or in patients over a wide age 
spectrum and do not offer a separate analysis of 
results for pediatric subsets. Two previous publica- 
tions from our institution addressed the outcome in 
children and young adults after operation for 
HOCM. Fiddler and associates 21 reported the cases 
of 16 patients younger than age 20 years who 
underwent operation f r HOCM. There were four 
deaths, one early and three late, over a 16-year 
follow-up giving an annual mortality rate of 1.6% 
per year. In the same report, 13 children had 
received no surgical therapy, and 7 died. Mohr and 
coworkers 22 evaluated the results in 47 young pa- 
tients with ages ranging from 1 to 38 years who 
underwent operation for HOCM. There was no 
early mortality; two late deaths occurred uring a 
follow-up that ranged up to 16 years for a linearized 
mortality rate of 0.3% per year. There has been no 
early or late mortality in the present review. These 
results compare favorably with e expected mortal- 
ity rate for pediatric patients who do not undergo 
operation of 4% to 6% per year (Fig. 6). 14 
Other institutions have also reported late results 
after operation in children that are better than the 
expected mortality for patients who do not undergo 
operation. Stone and colleagues s at the National 
Institutes of Health analyzed the outcome in 17 
pediatric patients who underwent operation because 
of HOCM. There was 1 perioperative death and 5 
late sudden deaths ranging from 3.8 to 21 years after 
operation; the annual mortality rate was 1.8% per 
year. Williams and Rebeyka 23 reported results in 25 
children with ages ranging from 2 months to 17 years 
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who underwent myectomy because of HOCM; there 
was no early death and only 1 late death, which 
occurred at reoperation 9 years after initial myec- 
tomy, in a follow-up that ranged up to 20 years. 
The patients in the present series were given some 
type of negative inotropic medication after opera- 
tion, even though the LVOT gradient and the mitral 
insufficiency were satisfactorily relieved. This philos- 
ophy was based on our historical observation that 
late survival in young patients was lowest before the 
development of medical or surgical therapy and was 
better when surgical treatment, especially LVM, 
became available. Survival was best when LVM was 
combined with postoperative administration of 
/3-adrenergic antagonists or calcium channel antag- 
onists when these medications became available. 
The improved results with the combined surgical 
and medical therapy were thought o be a result in 
part of suppression of sudden late, presumably 
arrhythmic, deaths. <s However, there is a recent 
trend in our institution among some cardiologists o 
discontinue administration of all negative inotropes 
in adults after successful LVM. Clearly, more data 
are required, preferably from randomized trials, 
regarding the appropriateness and effectiveness of
treatment with postoperative negative inotropes in 
preventing late arrhythmic deaths. 
In most instances, mitral insufficiency associated 
with HOCM is reduced to a negligible degree when 
the LVOT obstruction is successfully abolished with 
septal myectomy. In the present series, mitral insuf- 
ficiency was minimal or absent in all patients but one 
at late follow-up. The single exception was the 
youngest patient who was born with severe cardiac 
failure and was 2 months old at initial operation; in 
this case LVOT obstruction redeveloped and new 
obstruction in the right ventricular outflow tract 
occurred. In some patients with long-standing mitral 
insufficiency associated with HOCM, a deformity of 
the anterior leaflet of the mitral valve is produced. 
This can often be corrected with a plicating suture. 9
Occasionally, mitral valve replacement is required 
when there are organic changes in the mitral valve 
that are not amenable to mitral valve repair. In 
general, we prefer to avoid mitral valve replacement 
whenever possible because of the potential prob- 
lems of thrombosis, thromboembolism, durability, 
infection, and anticoagulation related to prosthetic 
mitral valves. 
Transaortic septal myectomy may present special 
problems in young patients because of limited expo- 
sure through the aortic valve anulus. Special care 
must be taken to avoid injury to the delicate aortic 
valve cusps during retraction for exposure of the 
hypertrophied septum, a complication that may 
necessitate subsequent aortic valve replacement. 8' 22 
Another special technical consideration i young 
patients relates to accurately judging the depth and 
length of the septal myectomy. Inadequate xcision 
will leave residual LVOT obstruction and limit 
symptomatic mprovement and patient survival. In 
our experience, adequate myectomy may be 
achieved in essentially all patients, but careful he- 
modynamic assessment after weaning from cardio- 
pulmonary bypass is mandatory for optimal results. 
Reinstitution of bypass and resection of additional 
septal muscle should be considered if the residual 
peak systolic gradient exceeds 20 mm Hg. Too deep 
a resection will create a ventricular septal defect 3' 6. 
this complication can readily be detected by intra- 
operative transesophageal echocardiography and 
then corrected at the same operation. 
Complete heart block is another complication 
that can be produced by traction against he aortic 
anulus or ventricular septum or by placement of the 
initial septal incision too close to the membranous 
septum. Despite the anatomic onstraints created by 
a small aortic root in pediatric patients, the preva- 
lence of permanent complete heart block can be 
kept low (no instances in the 25 patients in the 
present series). 
LVOT obstruction may recur in pediatric patients 
after initial successful myectomy, but the prevalence 
is unknown. In the present series, two children 
required repeat septal mYectomy 3.2 and 12.4 years 
after the initial procedure, respectively. Both pa- 
tients survived and currently remain free of LVOT 
obstruction. Williams and Rebeyka 23 suggested that 
children appear to have an increased risk of reop- 
eration for LVOT obstruction in that 3 of 25 
patients reported in their review required repeat 
myectomy with a range from 10 months to 9 years 
after initial operation. They compared these results 
with those in 139 adults who underwent septal 
myectomy for HOCM, none of whom required 
repeat operation because of recurrent gradients. 
Stone and associates s reported provokable LVOT 
gradients of 40 and 48 mm Hg in two pediatric 
patients at follow-up after septal myectomy. 
Recently, dual-chamber pacing has been pro- 
posed as an alternative to surgical treatment for 
relief of symptoms in patients with HOCM. 24' 25 An 
acute decrease in gradient may be produced by 
atrioventricular sequential pacing with appropri- 
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ately timed PR intervals, and symptomatic improve- 
ment has been reported with short-term follow-up. 
The mechanism responsible for the decrease in 
LVOT gradient is believed to be the abnormal 
septal motion produced by early pacing at the right 
ventricular apex. Also, there may be a late reduction 
of gradient related to ventricular emodeling and 
dilationY If effective in the long term, dual-cham- 
ber pacing would be appealing because it would 
avoid heart operation, it could be done by all 
cardiologists and surgeons with pacemaker exper- 
tise, and it would not require specialized referral 
centers. However, if dual-chamber pacing fails to 
provide an effective reduction of cardiac symptoms 
and LVOT gradient, operation is then required, and 
the patient has the added expense, inconvenience, 
and risk of another procedure. 
Short-term studies at our institution have shown 
favorable results in some patients after dual-cham- 
ber pacing. 26 However, hemodynamic deterioration 
has occurred in other patients in whom the LVOT 
gradient increased, the pulmonary artery pressure 
increased, and the cardiac output fell. In nearly all 
patients, diastolic function deteriorated and left 
atrial pressure increased; the long-term implications 
of these findings are unknown. 
Although symptoms may be relieved in some 
patients after dual-chamber pacing, there are differ- 
ences in the degree of reduction of the LVOT 
gradients compared with that obtained with surgical 
myectomy. In a previous report from our institution, 
myectomy produced an 87% decrease in mean 
gradient, 3 much greater than the 56% decrease 
achieved by pacing, 24'25 and the mean residual 
gradient was less with operation (9 mm Hg after 
LVM compared with 38 mm Hg with pacing). In the 
present series, there was an immediate 89% reduc- 
tion in intraoperative LVOT gradient o a mean 
residual gradient of 6.6 mm Hg after myectomy. The 
relief of LVOT obstruction was maintained in most 
patients at late follow-up; the mean echocardio- 
graphic maximum instantaneous gradient (14.2 mm 
Hg) was reduced 86% from the mean preoperative 
gradient (99.9 mm Hg). The relatively high residual 
LVOT gradient in patients treated with dual-cham- 
ber pacemakers may be important. A residual gra- 
dient of 15 mm Hg or greater was found to be an 
independent predictor of mortality after surgical 
myectomy in a previous report from our institution. 3 
Mitral insufficiency contributes ubstantially to 
symptoms of dyspnea in many patients with HOCM; 
the present review and previous reports from our 
institution 3 and others 2°' 23 demonstrate hat septal 
myectomy alone provides significant reduction of 
mitral insufficiency in most patients. It is not known 
how effectively dual-chamber pacing reduces the 
severity of mitral insufficiency. In addition, there are 
no data available yet to show that dual-chamber 
pacing reduces the threat of sudden death or im- 
proves survival of patients with HOCM. 
The comparative merits of septal myectomy ver- 
sus dual-chamber pacing are now being discussed. 27 
As the experience with dual-chamber pacing in- 
creases and lengthens, results will be compared with 
those of the more than 20-year experience with 
septal myectomy. Prospective studies to evaluate the 
mechanism and efficacy of dual-chamber pacing and 
proposed randomized trials of pacemaker versus 
myectomy will help to determine the relative role of 
each in the treatment of children and adults with 
HOCM. 
In summary, relief of LVOT obstruction was 
initially accomplished in all of the young patients in 
the present series, and 96% have had significant 
improvement in preoperative symptoms. There was 
no early or late mortality. We conclude that ex- 
tended LVM is a safe and effective means of reliev- 
ing cardiac symptoms, reducing LVOT gradient, 
and correcting mitral insufficiency in pediatric pa- 
tients. Myectomy can be accomplished with a low 
incidence of recurrent LVOT obstruction, and it 
provides excellent late survivorship that compares 
favorably with the natural history of the disease. 
We thank Duane M. Ilstrup, MS, for advice on the 
statistical analyses and Merrilee Rogotzke for excellent 
secretarial support in the preparation of this manuscript. 
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Discussion 
Dr. Michel N. Ilbawi (Oak Brook, Ill.). I congratulate 
the authors for these excellent results in children with this 
difficult problem. This important work brings to focus 
several points that are extremely important concerning 
the surgical management of obstructive cardiomyopathy 
in pediatric patients. 
The first point relates to the timing of operation. In the 
past, the initial treatment of patients with this lesion was 
primarily medical in the early stages. Operation was 
reserved until symptoms occurred or there was a severe 
onset of left ventricular hypertension. Encouraged by the 
early results, such as reported by the authors, we have 
operated on these patients earlier in the course of the 
disease. We attempted to relieve the pressure gradient 
before significant myocardial fibrosis or damage occurred. 
We are hoping that with this early intervention we can 
improve on the long-term outcome of this difficult prob- 
lem. Would the authors please comment on their present 
philosophy concerning timing of operation? Do they still 
wait until the development of severe left ventricular 
hypertension or onset of symptoms before they recom- 
mend operation, or have they liberalized their indications 
for operation? 
Another important point is the extent of resection. We 
believe that aggressive muscle resection is needed to 
achieve adequate and lasting relief of obstruction. We thin 
the septum almost o the level of the intact endocardium 
on the right side. In a few patients we have used patch 
enlargement of the LVOT, the so-called modified Konno 
procedure, to deal with severe obstruction. Do the authors 
have objective guidelines of how deep the muscle resec- 
tion should be? 
The third point concerns mitral valve operation and 
abnormality. I notice that the authors elected to plicate 
the valve in only 2 of 17 patients with moderate or severe 
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regurgitation. What are the authors' recommendations 
concerning when and what to do for the mitral valve? 
The fourth point is that patients with obstructive car- 
diomyopathy that present in early life are a different 
subset of patients. They are categorized by severe obstruc- 
tion and have different short- and long-term outcomes. 
Did the authors analyze their results with this subset of 
patients? 
Finally, this is an intriguing paper in the sense that the 
data imply that operation has improved survival in this 
group of patients. Do the authors maintain that survival 
has improved in their experience despite the absence of 
exercise testing or dobutamine stress echocardiographic 
evaluation? 
Dr. Theodoro. In regard to our present philosophy on 
the timing of operation, I believe with the favorable 
results operation has now been shown to achieve that 
patients will be referred for operation earlier in the 
clinical course than they were in the beginning of this 
series. Nevertheless, the principal reason for offering 
operation at our institution is still persistence of symptoms 
associated with significant outflow tract gradients after 
adequate medical therapy. However, a few patients with- 
out symptoms are accepted for operation if they have fixed 
resting gradients in excess of 80 to 100 mm Hg. 
The depth of septal excision depends on the thickness 
of the basal septum. Before the availability of intraoper- 
ative transesophageal chocardiography, septal thickness 
was assessed by bimanual palpation through the opened 
aorta. Currently we can obtain exact measurement of 
septal thickness with intraoperative transesophageal cho- 
cardiography. It is our philosophy that resection of ap- 
proximately two thirds of the thickness of the septal bulge 
is required for adequate relief of outflow tract obstruction. 
We have not needed to use the modified Konno pro- 
cedure for primary operation in patients with HOCM, but 
it is an effective technique for relieving recurrent or more 
complex forms of LVOT obstruction. In one patient in 
whom recurrent obstruction and unexplained severe aor- 
tic insufficiency developed 12 years after initial myectomy, 
reresection and a Konno procedure were done with the 
use of an aortic homograft. That patient is currently 
completely free of symptoms with a competent aortic 
valve 5 years after the second operation. 
With regard to anterior leaflet plication, this is done if 
there is redundancy or distortion of the anterior leaflet 
that appears to contribute to LVOT obstruction. This is 
more apt to occur in the adult population with long- 
standing HOCM. In the absence of organic hanges in the 
mitral valve, an adequate septal resection has relieved the 
mitral valve insufficiency in the vast majority of our 
patients. The mitral valve is evaluated again by trans- 
esophageal echocardiography after myectomy. Any resid- 
ual mitral insufficiency is treated by standard repair tech- 
niques. 
Clearly the infant subset is a difficult group of patients 
that has a poorer short- and long-term outcome. Dr. 
Maron from the National Institutes of Health has re- 
ported the cases of 11 patients with congestive heart 
failure in infancy caused by HOCM, nine of whom died 
within the first year of life. We had one infant patient in 
this subset, who was born with congestive heart failure. 
Recurrent LVOT and also right ventricular outflow tract 
obstruction have developed in this patient 5 years after 
operation at age 2 months. She is the only patient in this 
series who was not in NYHA class I or II at follow-up. 
With regard to the last question, we believe that the 
symptomatic improvement and especially the longevity of 
this series of surgical patients are clearly superior to those 
published on the natural history of children with HOCM 
who have symptoms and do not undergo peration. 
Dr. Richard A, Jonas (Boston, Mass.). Would the 
authors be a little bit more specific on the indications for 
operation? They have suggested that there may be an 
indication to operate to enhance longevity, in other words, 
not just to relieve symptoms, which has been the tradi- 
tional indication for operation. If we accept that, then 
what are their indications in terms of pressure gradient? 
For example, I note that some patients had a pressure 
gradient as low as 20 mm Hg: are asymmetric septal 
hypertrophy, a 20 mm Hg gradient, and no symptoms then 
sufficient indications to operate? 
Dr. Theodoro. In the patients with symptoms, the lowest 
resting or inducible preoperative gradient was 50 mm Hg. 
(The gradient of 20 mm Hg was measured intraopera- 
tively during general anesthesia.) A gradient of 50 mm Hg, 
by itself, without associated symptoms, would not gener- 
ally be considered an indication for operation. The results 
of this review and other surgical series clearly show that 
longevity is increased by operation in patients with symp- 
toms with LVOT obstruction, but improved longevity has 
not been demonstrated for patients without symptoms or 
for patients with mild or absent gradients. The five 
patients without symptoms in our series had fixed resting 
gradients in excess of 80 to 100 mm Hg. The referring 
pediatric ardiologist urged operation, believing the prog- 
nosis for the patient would be as bad as for patients with 
valvular aortic stenosis and similar gradients. Although 
this reasoning seems logical, the numbers are small and 
statistical data are lacking. 
Dr. William G. Williams (Toronto, Ontario, Canada). I
would like to ask a question about the management of
complex and potentially fatal arrhythmias. In our experi- 
ence of 230 patients with this disease the results are 
almost identical to what you have reported today. When 
we stratify the results by age, the outlook for children 
younger than age 18 is not different from that of the 
overall series. The prevalence of reoperation is also 
identical to yours at 94% at l0 years. 
Importantly, when we look at the stratification of the 
patients who have syncope, who comprised 20% of the 
current series, the long-term survival is identical in pa- 
tients with syncope versus that in those without. As you 
pointed out, the natural history of the disease is for 
sudden death in many patients; these deaths are presumed 
caused by ventricular tachycardia. However, after myec- 
tomy, sudden death is uncommon in our experience. We 
have only had two sudden, unexpected eaths in more 
than 200 patients treated by operation. 
In this series there was one AICD implantation done at 
the time of operation and two after operation, and I am 
interested in the follow-up in those patients. This becomes 
a problem in patients who have sudden death. Our 
attitude has been to take a wait-and-see approach, and so 
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far that has been reasonably successful. In the three 
patients who did have AICD implantation, do the authors 
have follow-up on whether the AICD triggered on the 
basis of an arrhythmia? Have late ventricular arrhythmias 
been a problem in their experience? 
Dr. Theodoro. Indications for implantation of an AICD 
are still evolving. In general, when ventricular tachycardia or
ventricular fibrillation has been documented before opera- 
tion, an AICD implantation is planned. Some cases of 
familial HOCM have a strong family history of sudden death 
at an early age; these patients are evaluated by preoperative 
electrophysiologic testing. If significant ventricular arrhyth- 
mias can be induced, an AICD implantation is planned. 
Some patients with serious postoperative ventricular ar- 
rhythmias also receive an AICD. With the advent of effective 
transvenous cardioverter defibrillators, our cardiologists 
have lowered their threshold for recommending an AICD 
considerably. In those patients who have received an AICD, 
the number of subsequent cardioversion/defibrillations has 
ranged from 0 to more than 22. 
Dr. George R. Daicoff (St. Petersburg, Fla.). I have just 
one comment and a question. The comment is we are 
getting a lot of resistance from our cardiologists saying 
that all the patients need is a pacemaker. This is an 
important landmark paper that should be used as a 
standard of comparison for any other therapy that is 
recommended. 
The question I have is this: after 5 years of follow-up 
with eehocardiograms and other diagnostic tests, what can 
the authors tell us about the flee wall? This might give us 
a clue as to how much of the LVOT obstruction is 
important in creating secondary left ventricular hypertro- 
phy versus how much of this is the basic underlying 
disease. Can the authors provide this information? 
Dr. Theodoro. The issue of whether left ventricular f ee 
wall hypertrophy regresses after relief of LVOT obstruc- 
tion is controversial. In our group's experience, we have 
no convincing evidence that there is any appreciable or 
consistent regression of left ventricular free wall hyper- 
trophy on follow-up echocardiograms. It appears to us 
that the free wall hypertrophy seen before operation 
results entirely or predominantly from inappropriate hy- 
pertrophy caused by genetic abnormalities, and this does 
not change appreciably even when the left ventricular 
pressure is reduced to normal levels by successful myec- 
tomy. The data presented in the rare literature reports in 
which consistent regression is said to occur are not 
convincing to us. 
